Drug Profile
Research programme: antimalarials - PLIVA/WRAIR
Alternative Names: Antimalarials research programme - PLIVA/WRAIR; Azithromycin analogues research programme - PLIVA/WRAIR; Research programme: antimalarials - Pliva Research Institute/WRAIRLatest Information Update: 16 Aug 2007
Price :
$50
*
At a glance
- Originator PLIVA Inc
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malaria
Most Recent Events
- 05 May 2006 GlaxoSmithKline aquires the research arm of PLIVA
- 20 Jul 2005 Preclinical trials in Malaria in USA (unspecified route)